Benefits and risks of induction immunosuppression in pediatric autoimmune liver disease from SPLIT Registry. (PubMed, Liver Transpl) - Oct 25, 2026 - "This study compared outcomes between corticosteroids only, anti-thymocyte globulin (ATG), and IL-2 receptor antagonists (IL2RA; Basiliximab/Daclizumab). No significant differences were observed in graft loss, mortality, disease recurrence, or post-transplant lymphoproliferative disorder up to five years post-transplant. In pediatric AILD, induction with IL2RA significantly reduces early acute rejection without increasing infection risks or compromising long-term graft and patient survival."
Journal • Autoimmune Hepatitis • Hepatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Primary Sclerosing Cholangitis • Transplant Rejection • Transplantation • IL2RA
|
|
; Anthony J Perkins; Chandrashekhar Avinash Kubal; Chaowapong Jarasvaraparn; Jean P Molleston; Kyla Tolliver; Richard Shane Mangus
|